Gene and Protein Information
Species	TM	AA	Chromosomal Location	Gene Symbol	Gene Name	Reference
Human	1	556	16p11.2	CD19	CD19 molecule	4
Mouse	1	547	7 69.01 cM	Cd19	CD19 antigen	4
Rat	-	547	1q36	Cd19	CD19 molecule

Database Links
Alphafold	P15391 (Hs), P25918 (Mm)
CATH/Gene3D	2.60.40.10
ChEMBL Target	CHEMBL3390821 (Hs)
Ensembl Gene	ENSG00000177455 (Hs), ENSMUSG00000030724 (Mm), ENSRNOG00000018311 (Rn)
Entrez Gene	930 (Hs), 12478 (Mm), 365367 (Rn)
Human Protein Atlas	ENSG00000177455 (Hs)
KEGG Gene	hsa:930 (Hs), mmu:12478 (Mm), rno:365367 (Rn)
OMIM	107265 (Hs)
Pharos	P15391 (Hs)
RefSeq Nucleotide	NM_001178098 (Hs), NM_009844 (Mm), NM_001013237 (Rn)
RefSeq Protein	NP_001171569 (Hs), NP_033974 (Mm), NP_001013255 (Rn)
UniProtKB	P15391 (Hs), P25918 (Mm)
Wikipedia	CD19 (Hs)

Download all structure-activity data for this target as a CSV file

Antibodies
Key to terms and symbols		Click column headers to sort
Antibody Sp. Action Value Parameter Reference inebilizumab Hs Binding 9.3 – 10.3 pKd 1 ⤷ pKd 9.3 – 10.3 (Kd 5x10-10 – 5x10-11 M) [1] blinatumomab Hs Binding 9.0 pKd 2 ⤷ pKd 9.0 (Kd 1x10-9 M) [2] Description: Binding of the single-chain Fv portion of blinatumomab to CD19. tafasitamab Hs Binding - - 3 ⤷ [3] loncastuximab tesirine Hs Binding - - 5 ⤷ [5]
Antibody Comments
A CD19-targeting ADC was disclosed during the 'First Disclosures of New Drug Candidates' session at the April 2023 (Orlando) meeting of the AACR: ABBV-319 is an anti-CD19 antibody with a potent glucocorticosteroid payload, that was developed for potential to treat B-cell malignancies (phase 1 NCT05512390). It is proposed to deliver anticancer activity, whilst minimising the risk of systemic steroid toxicities (by selectively targeting to CD19 +ve cells), and promotes enhanced antibody-dependent cellular cytotoxicity (ADCC) as a result of afucosylation of its Fc region.

Immunopharmacology Comments

CD19 is a B cell antigen used as a biomarker for normal and neoplastic B cells, and follicular dendritic cells. Anti-CD19 monoclonal antibodies are being investigated for potential clinical utility in oncology, transplantation and autimmune diseases (e.g. inebilizumab). Blinatumomab is a bispecific CD19/CD3e mAb already approved as a treatment for Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL), an uncommon form of ALL.

Cell Type Associations

Immuno Cell Type:  B cells Cell Ontology Term:   B cell (CL:0000236)

Immuno Process Associations

Immuno Process:  Inflammation

Immuno Process:  Immune regulation

Immuno Process:  Cellular signalling

Immuno Process:  B cell (activation)

Immuno Process:  Immune system development

Immuno Process:  T cell (activation)

Immuno Disease Associations

Disease Name:  Acute lymphocytic leukemia (ALL) Disease Synonyms:  no synonynms Comment:  CD19 is one of the molecular targets of the bi-specific antibody drug blinatumomab (also binds CD3e). Disease X-refs:  OMIM: 613065 References:

Clinically-Relevant Mutations and Pathophysiology
Disease:  Immunodeficiency, common variable, 3; CVID3 Synonyms: Common variable immunodeficiency [Orphanet: ORPHA1572] [Disease Ontology: DOID:12177] Disease Ontology: DOID:12177 OMIM: 613493 Orphanet: ORPHA1572